Published in final edited form as:

Tetrahedron Lett. 2000 December 16; 41(15): 10121–10125. doi:10.1016/S0040-4039(00)01803-7.

2,5-Anhydro sugar diacid and 2,5-anhydro sugar diamine based C_2 symmetric peptidomimetics as potential HIV-1 protease inhibitors

T. K. Chakraborty^a, Subhash Ghosh^a, M. H. V. Ramana Rao^a, A. C. Kunwar^a, H. Cho^b, and A. K. Ghosh^b

^aIndian Institute of Chemical Technology, Hyderabad 500 007, India

^bDepartment of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, IL 60607, USA

Abstract

Conformationally constrained molecular frameworks of the 2,5-anhydro sugar diacid (**9**) and 2,5-anhydro sugar diamines (**10**, **11**) were used to construct architecturally beautiful novel C_2 symmetric peptidomimetics **1–8**. Although none of these compounds showed any significant HIV-1 protease inhibitory activity, further refinements in design may lead to protease inhibitors based on these rigid carbohydrate-derived scaffolds.

Among the several specific targets in the cell cycle of the human immunodeficiency virus (HIV), the virally encoded homodimeric HIV-1 protease, which is an aspartyl protease required for maturation of the infectious virion, has emerged as a promising target leading to the design and evaluation of a vast array of compounds with diverse structural motifs as possible inhibitors, some of which have already been approved for the treatment of AIDS.^{1–6}

We describe herein the development of a new class of compounds **1–8** as potential HIV-1 protease inhibitors that are based on carbohydrate–peptide hybrid structures. In this approach, identical peptide chains are anchored on both sides of a core carbohydrate motif—a C_2 symmetric 2,5-anhydro sugar diacid or sugar diamine—leading to the formation of C_2 symmetric peptidomimetics.⁷ Carbohydrate-based molecular designs are increasingly drawing chemists' attention.^{8,9} Detailed studies on the development of new HIV-1 protease inhibitors based on acyclic carbohydrates have recently been reported.^{10–12} It is also being increasingly felt that small molecule protease inhibitors need to have restricted degrees of freedom. The success of cyclic urea based inhibitors supports this feeling.^{13,14} This has prompted us to look for cyclic carbohydrate based core foundations as conformationally rigid scaffolds to build a new class of molecular frameworks as potential protease inhibitors.

Two different types of cyclic carbohydrate framework—sugar diacid and sugar diamine—are employed in our designs. These molecules are 2,5-anhydro-D-idaric acid (**9**), 1,6-diamino-2,5-anhydro-1,6-dideoxy-D-itol (**10**) and 1,6-diamino-2,5-anhydro-1,6-dideoxy-

D-mannitol (**11**). The sugar diacid **9**, to the best of our knowledge, was reported for the first time by us along with the synthesis of the first sugar diacid based peptidomimetic **1**.¹⁵ The twofold symmetry of the molecule was evident in its ¹H and ¹³C NMR spectra which showed peaks for only half of the molecule. Two-dimensional NMR studies in combination with constrained molecular dynamics (MD) simulations revealed a very ordered *C*₂ symmetric structure for **1**, consisting of identical intramolecular H bonds at the two ends between the LeuNH→sugar-OH. A very small temperature coefficient for the LeuNH chemical shift ($\delta/\ T=-1.2$ ppb K⁻¹) was observed in DMSO-*d*₆. The presence of two ‘*cis*-β-hydroxycarboxyl’ moieties, the core structural motif believed to be responsible for such intramolecular H bonds,¹⁶ on two sides of the tetrahydrofuran ring nucleated identical β-turn-like structures in **1** at both ends.

To further these studies, we decided to prepare a few more *C*₂ symmetric peptidomimetics and examine their structures and properties, especially HIV-1 protease inhibition activities, as these compounds structurally resemble many well-established *C*₂ symmetric HIV-1 protease inhibitors. In this paper we describe the results of that investigation.

Compounds **2** and **4** were prepared in 60 and 70% yields, respectively, from **1** in two steps: saponification followed by the reaction with *p*-bromoaniline (for **2**) or H₂N-Ala-OMe (for **4**)¹⁷ under standard solution phase peptide synthesis conditions using 1-hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (EDCI) as coupling agents and amine-free dry DMF and/or dry CH₂Cl₂ as solvents. The synthesis of **3** was carried out following the same procedure described earlier for the synthesis of **1**.¹⁵ The di-*O*-benzyl derivative of 2,5-anhydro-D-idaric acid¹⁵ (**9**) was treated with an excess of amino-terminal free peptide molecule to furnish **3** in 55% yield.

Structural studies of these molecules (**2–4**) did not reveal significant turn structures in solution as seen in **1**. While compounds **3** and **4** still maintained *C*₂ symmetric structures as shown by their NMR studies in DMSO-*d*₆, the *p*-bromoanilide derivative **2** lost its symmetry with each of its amide protons showing two peaks in the same solvent. Its LeuNH chemical shifts, however, exhibited low temperature coefficients of -2.1 and -2.4 ppb K⁻¹ maintaining their participation in intramolecular H bonding, similar to the one observed in **1**, albeit weaker. Hydrogenation of **3** gave a complex mixture of products and its structure and properties were studied in the Bn-protected form, which showed high temperature

coefficients for the amide proton chemical shifts. The temperature coefficient of the LeuNH peak in **4** was -2.8 ppb K^{-1} , indicating gradual loss in its ability to nucleate the desired secondary structure, probably due to the increased steric hindrance.

Next, we turned our attention to the remaining peptidomimetics, **5–8**, based on sugar diamines **10** and **11**. Syntheses of **5** and **6** were accomplished according to Scheme 1. The starting material **12**, prepared from 1,3:4,6-di-*O*-benzylidene-D-mannitol,¹⁵ was converted to **14** in four steps—ditosylation, azidation and selective azide reduction, followed by protection in situ using Boc_2O for purification purposes giving the di-*N*-Boc-protected intermediate **14** in 50% overall yield from **12**. Purified **14** was treated with TFA in CH_2Cl_2 and peptide chains were attached at both ends using EDCI–HOBt as coupling reagents. Finally, debenzoylation using H_2 –Pd–C (10%) in MeOH furnished the final product **5** (and **6**) in ~70% overall yield.¹⁸

Syntheses of **7** and **8** from 3,4-di-*O*-benzyl-1,2:5,6-diisopropylidene-D-mannitol (**15**) are depicted in Scheme 2. Monodeprotection gave a diol intermediate whose primary hydroxyl was selectively acylated to get a 55% yield of acetate **16**. Conversion of **16** to the terminal epoxide **17** was achieved in two steps in 86% yield. Acid-catalyzed cycloetherification of **17** went smoothly to furnish the 2,5-anhydro-D-mannitol framework **18**, which was converted to the diamine and finally to the desired products **7** and **8**,¹⁹ following the procedure described above in Scheme 1.

All the sugar diamine based mimetics, **5–8**, had C_2 symmetric structures in solution, as determined by their ^1H NMR studies in $\text{DMSO}-d_6$, which showed peaks for only half of the molecule. However, very high temperature coefficients for all of their amide proton chemical shifts indicated the absence of any intramolecular H bonding in these molecules.

The potential of the peptidomimetics **1–8** as HIV protease inhibitors were evaluated using an assay protocol developed by Toth and Marshall.²⁰ Unfortunately, none of these compounds showed any enzyme inhibitory activities up to 2 μM inhibitor concentration. The large distances between the phenyl rings of the P1/P1' positions are probably responsible for their low activities. Efforts are now underway to improve our designs and to prepare active HIV-1 protease inhibitors from conformationally constrained 2,5-anhydro sugar-based scaffolds.

Acknowledgements

Authors wish to thank the CSIR, New Delhi for research fellowships (to S.G. and M.H.V.R.R.) and a Young Scientist Award Research Grant (to T.K.C.).

References

1. Leung D; Abbenante G; Fairlie DP J. Med. Chem 2000, 43, 305–341 and references cited therein. [PubMed: 10669559]
2. Molla A; Granneman GR; Sun E; Kempf DJ Antiviral Res. 1998, 39, 1–23. [PubMed: 9754946]
3. Cohen J Science 1996, 272, 1880–1883. [PubMed: 8658155]
4. Vacca JP In Methods in Enzymology, Kus LC; Shafer JA, Eds.; Academic Press: San Diego, 1994; Vol. 241, pp. 311–334. [PubMed: 7854186]

5. Kempf DJ In Methods in Enzymology, Kus LC; Shafer JA, Eds.; Academic Press: San Diego, 1994; Vol. 241, pp. 334–354. [PubMed: 7854187]
6. Wlodawer A; Erickson JW Annu. Rev. Biochem 1993, 62, 543–585. [PubMed: 8352596]
7. For a recent article on C2 symmetric HIV-1 protease inhibitors see: Keinan S; Avnir D J. Am. Chem. Soc 2000, 122, 4378–4384 and references cited therein.
8. Schweizer F; Hindsgaul O Curr. Opin. Chem. Biol 1999, 3, 291–298. [PubMed: 10359718]
9. Drickamer K; Dwek RA Curr. Opin. Struct. Biol 1995, 5, 589–590. [PubMed: 8574692]
10. Alterman M; Björnsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren P; Nillroth U; Unge T; Hallberg A; Samuelsson BJ Med. Chem 1998, 41, 3782–3792.
11. Zuccarello G; Bouzide A; Kvarnström I; Niklasson G; Svensson SCT; Brisander M; Danielsson H; Nillroth U; Karlén A; Hallberg A; Classon B; Samuelsson BJ Org. Chem 1998, 63, 4898–4906.
12. Wachtmeister J; Mühlman A; Classon B; Kvarnström I; Hallberg A; Samuelsson B Tetrahedron 2000, 56, 3219–3225.
13. Pierce ME; Harris GD; Islam Q; Radesca LA; Storace L; Waltermire RE; Wat E; Jadhav PK; Emmett GC J. Org. Chem 1996, 61, 444–450. [PubMed: 11666958]
14. Lam PYS; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN; Chang C-H; Weber PC; Jackson DA; Sharpe TR; Erickson-Viitanen S Science 1994, 263, 380–384. [PubMed: 8278812]
15. Chakraborty TK; Ghosh S; Jayaprakash S; Sharma JARP; Ravikanth V; Diwan PV; Nagaraj R; Kunwar AC J. Org. Chem 2000, 65, 6441–6457. [PubMed: 11052087]
16. Chakraborty TK; Jayaprakash S; Diwan PV; Nagaraj R; Jampani SRB; Kunwar AC J. Am. Chem. Soc 1998, 120, 12962–12963.
17. Selected physical data of 4. Rf=0.4 (silica, EtOAc); $[\alpha]_D^{20}$ -12.8 (c0.5, CHCl₃); 1H NMR (500 MHz, DMSO-d₆): δ 8.09 (d, J=6.8 Hz, 2H, AlaNH), 8.07 (d, J=8.5 Hz, 2H, PheNH), 7.72 (d, J=8.2 Hz, 2H, LeuNH), 7.28–7.19 (m, 10H, aromatic), 5.96 (d, J=2.8 Hz, 2H, OH), 4.56 (d, J=2.8 Hz, 2H, C2- and C5-H), 4.50 (ddd, J=10.4, 8.5, 3.4 Hz, 2H, PheαH), 4.28 (ddd, J=9.8, 8.2, 5.1 Hz, 2H, LeuαH), 4.23 (m, 2H, AlaαH), 4.16 (t, J=2.8 Hz, 2H, C3- and C4-H), 3.60 (s, 6H, OCH₃), 3.19 (dd, J=14.1, 3.4 Hz, 2H, PheβH), 2.96 (dd, J=14.1, 10.4 Hz, 2H, PheβH'), 1.63 (m, 2H, LeuγH), 1.44 (ddd, J=13.7, 8.6, 5.1 Hz, 2H, LeuβH), 1.38 (ddd, J=13.7, 9.8, 5.6 Hz, 2H LeuβH'), 1.29 (d, J=7.3 Hz, 6H, AlaβH), 0.89 (d, J=7.2 Hz, 6H, LeuδH), 0.8 (d, J=7.2 Hz, 6H, LeuδH'); 13C NMR (125 MHz, CDCl₃): δ 172.92, 172.25, 170.51, 169.47, 135.79, 128.94, 128.91, 127.51, 83.26, 77.92, 54.19, 52.43, 51.35, 48.46, 40.39, 36.55, 24.48, 22.89, 21.72, 17.49.
18. Selected physical data of 6. Rf=0.3 (silica, EtOAc); $[\alpha]_D^{20}$ -23.3 (c0.5, CHCl₃); 1H NMR (500 MHz, DMSO-d₆): δ 8.04 (t, J=5.6 Hz, 2H, sugarNH), 7.85 (d, J=8.4 Hz, 2H, PheNH), 7.24–7.14 (m, 10H, aromatic), 6.64 (d, J=9.0 Hz, 2H, ValNH), 5.05 (d, J=3.6 Hz, 2H, OH), 4.56 (ddd, J=9.2, 8.4, 5.1 Hz, 2H, PheαH), 3.91 (dt, J=6.8, 2.8 Hz, 2H, C2- and C5-H), 3.82 (dd, J=3.6, 2.8 Hz, 2H, C3- and C4-H), 3.70 (dd, J=9.0, 7.0 Hz, 2H, ValαH), 3.24 (ddd, J=13.6, 6.8, 5.8 Hz, 2H, C1- and C6-H), 3.12 (ddd, J=13.6, 6.8, 5.6 Hz, 2H, C1- and C6-H'), 2.94 (dd, J=13.7, 5.1 Hz, 2H, PheβH), 2.79 (dd, J=13.7, 9.2 Hz, 2H, PheβH'), 1.81 (m, 2H, ValβH), 1.37 (s, 18H, Boc), 0.71 (d, J=6.6 Hz, 6H, ValγH), 0.67 (d, J=6.6 Hz, 6H, ValγH'); 13C NMR (125 MHz, DMSO-d₆): δ 171.38, 170.87, 155.27, 137.47, 129.11, 127.91, 126.15, 78.53, 78.06, 75.84, 59.99, 53.48, 38.29, 37.92, 30.36, 28.11, 19.02, 18.05.
19. Selected physical data of 8. Rf=0.45 (silica, 10% MeOH in CHCl₃); $[\alpha]_D^{20}$ -29.5 (c0.55, CHCl₃); 1H NMR (500 MHz, DMSO-d₆): δ 8.07 (dd, J=6.3, 5.2 Hz, 2H, sugarNH), 7.81 (d, J=8.7 Hz, 2H, PheNH), 7.23–7.14 (m, 10H, aromatic), 6.65 (d, J=9.2 Hz, 2H, ValNH), 5.17 (d, J=3.9 Hz, 2H, OH), 4.60 (ddd, J=9.7, 8.7, 4.3 Hz, 2H, Phe αH), 3.77–3.70 (m, 4H, C2-, C3-, C4- and C5-H), 3.69 (dd, J=9.2, 6.8, 1H, ValαH), 3.27 (dt, J=13.2, 5.2 Hz, 2H, C1- and C6-H), 3.19 (dt, J=13.2, 6.3 Hz, 2H, C1- and C6-H'), 2.97 (dd, J=13.7, 4.3 Hz, 2H, PheβH), 2.77 (dd, J=13.7, 9.7 Hz, 2H, PheβH'), 1.79 (m, 2H, ValβH), 1.37 (s, 18H, Boc), 0.69 (d, J=6.8 Hz, 6H, ValγH), 0.64 (d, J=6.8 Hz, 6H, ValγH'); 13C NMR (125 MHz, DMSO-d₆): δ 171.10, 170.86, 155.27, 137.64, 129.18, 127.87, 126.11, 82.12, 78.81, 78.08, 60.10, 53.41, 41.10, 38.13, 30.41, 28.13, 19.04, 18.08.
20. Toth MV; Marshall GR Int. J. Pep. Prot. Res 1990, 36, 544–550.

Scheme 1.
Synthesis of **5** and **6**

Scheme 2.
Synthesis of **7** and **8**